Guided Radiofrequency Ablation Using the CARTO® 3 and NavX™ Systems for the Treatment of Paroxysmal Atrial Fibrillation (CO1)
Comparative Study of Guided Radiofrequency Ablation Using the CARTO® 3 and NavX™ Systems for the Treatment of Paroxysmal Atrial Fibrillation
Sponsor: Biosense Webster, Inc.
Terminated
Enrollment challenges
Other terminated trials from Biosense Webster, Inc.
- Non-ischemic Cardiomyopathy · Nov 2024
- Ventricular Tachycardia · Phase EARLY_PHASE1 · Oct 2024
- Stroke · Phase PHASE3 · Dec 2023
- Atrial Fibrillation · Phase NA · Jun 2023
- Paroxysmal Atrial Fibrillation · Phase NA · Oct 2022
More terminations from Biosense Webster, Inc.
Other Paroxysmal Atrial Fibrillation trials with similar outcome
Listed as NCT01036724, this observational or N/A phase trial focuses on Paroxysmal Atrial Fibrillation and remains terminated or withdrawn. Sponsored by Biosense Webster, Inc., it has been updated 9 times since 2009, reflecting limited change activity. This study contributes longitudinal data to the cardiovascular research landscape.
Status Flow
Change History
9 versions recorded-
Sep 2025 — Present [monthly]
Terminated
-
Sep 2024 — Sep 2025 [monthly]
Terminated
-
Jul 2024 — Sep 2024 [monthly]
Terminated
-
Dec 2021 — Jul 2024 [monthly]
Terminated
-
Jan 2021 — Dec 2021 [monthly]
Terminated
▶ Show 4 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Terminated
-
Apr 2018 — Jun 2018 [monthly]
Terminated
Phase: NA → None
-
Oct 2017 — Apr 2018 [monthly]
Terminated NA
-
Jan 2017 — Oct 2017 [monthly]
Terminated NA
First recorded
Nov 2009
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Biosense Webster, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .